摘要
我国药品伦理审查工作的展开,对保护受试者权益起了重要作用。应从打造机构伦理委员会的认证体系、保持独立性、完整地贯彻知情同意等方面予以完善,以确保全部受试者的权益得到进一步的保障。
The ethical review of new drugs has already been developed in China, and played an important role in the right protection of the subject. To ensure the right of the subject is fully protected, it should be improved in the aspects of constructing a certification system of the ethics committee, maintaining independence and performing informed consent completely.
出处
《中国医学伦理学》
2009年第3期84-85,94,共3页
Chinese Medical Ethics
关键词
伦理审查
受试者权益保护
医药安全
Ethical Review
Right Protection of A Subject
Medical and Drug Safety
